ATE366585T1 - Separin inhibitoren, verfahren zu ihren identifizierung und ihre anwendungen - Google Patents

Separin inhibitoren, verfahren zu ihren identifizierung und ihre anwendungen

Info

Publication number
ATE366585T1
ATE366585T1 AT00909162T AT00909162T ATE366585T1 AT E366585 T1 ATE366585 T1 AT E366585T1 AT 00909162 T AT00909162 T AT 00909162T AT 00909162 T AT00909162 T AT 00909162T AT E366585 T1 ATE366585 T1 AT E366585T1
Authority
AT
Austria
Prior art keywords
identifying
separin
inhibitors
applications
sister chromatid
Prior art date
Application number
AT00909162T
Other languages
English (en)
Inventor
Frank Uhlmann
Kim Nasmyth
Jan-Michael Peters
Irene Waizenegger
Sara Buonomo
Rosemary Clyne
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of ATE366585T1 publication Critical patent/ATE366585T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT00909162T 1999-02-15 2000-02-14 Separin inhibitoren, verfahren zu ihren identifizierung und ihre anwendungen ATE366585T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99102962A EP1029547A1 (de) 1999-02-15 1999-02-15 Pharmazeutische wirksame stoffe und Verfahren zu zu ihrer Identifizierung

Publications (1)

Publication Number Publication Date
ATE366585T1 true ATE366585T1 (de) 2007-08-15

Family

ID=8237559

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00909162T ATE366585T1 (de) 1999-02-15 2000-02-14 Separin inhibitoren, verfahren zu ihren identifizierung und ihre anwendungen

Country Status (9)

Country Link
US (1) US7410774B1 (de)
EP (2) EP1029547A1 (de)
JP (1) JP4377073B2 (de)
AT (1) ATE366585T1 (de)
CA (1) CA2362794C (de)
DE (1) DE60035490T2 (de)
ES (1) ES2290016T3 (de)
MX (1) MXPA01008214A (de)
WO (1) WO2000048627A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
EP1227160A1 (de) * 2001-01-19 2002-07-31 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verbindungen, die die Trennung von Schwesterchromatiden modulieren, und Verfahren für das Identifizieren dieser Verbindungen
EP1321529A1 (de) * 2001-12-21 2003-06-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zum Nachweis von Modulatoren von Schwesterchromatid Kohäsion
US20130109737A1 (en) * 2010-02-09 2013-05-02 Richard A. Young Mediator and cohesin connect gene expression and chromatin architecture
WO2020263909A1 (en) * 2019-06-24 2020-12-30 The Regents Of The University Of California Methods for preparation of active separase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
CA2274734A1 (en) * 1996-12-20 1998-07-02 Board Of Regents, The University Of Texas System Proteins and compositions for modulating mitosis
US6004933A (en) * 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
EP1227160A1 (de) * 2001-01-19 2002-07-31 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verbindungen, die die Trennung von Schwesterchromatiden modulieren, und Verfahren für das Identifizieren dieser Verbindungen

Also Published As

Publication number Publication date
DE60035490D1 (de) 2007-08-23
JP2002538781A (ja) 2002-11-19
CA2362794C (en) 2010-11-09
JP4377073B2 (ja) 2009-12-02
WO2000048627A1 (en) 2000-08-24
ES2290016T3 (es) 2008-02-16
MXPA01008214A (es) 2003-07-21
EP1154788A1 (de) 2001-11-21
US7410774B1 (en) 2008-08-12
CA2362794A1 (en) 2000-08-24
EP1029547A1 (de) 2000-08-23
EP1154788B9 (de) 2007-09-12
DE60035490T2 (de) 2008-05-08
EP1154788B1 (de) 2007-07-11

Similar Documents

Publication Publication Date Title
WO2004020458A3 (en) Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents
AU2002305796A1 (en) Opns as modifiers of the p53 pathway and methods of use
WO2003071376A3 (en) Method and system for distributing geographical addresses across the surface of the earth
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
DE60227559D1 (de) Beschichtungsverfahren und zusammensetzung
ATE511672T1 (de) System und verfahren für sichere interplattform- und intraplattform-kommunikationen
WO2002003687A3 (en) Equipment and techniques for increasing the dynamic range of a projection system
EE04511B1 (et) Kärg-raadiosidesüsteem, meetod geograafilise informatsiooni levitamiseks ja esitamiseks SMS-sõnumifunktsiooni abil ning raadiosideseade
WO2003099210A3 (en) Methods of modulating tubulin deacetylase activity
WO2004093370A3 (en) Distributed power management
BRPI0507776A (pt) métodos de modular a atividade de citocina; reagentes relacionados
WO1999019513A3 (en) Methods for detecting compounds which modulate the activity of an lpa receptor
ATE328112T1 (de) Anaplastisches lymphoma kinase testverfahren, reagenzien und kompositionen davon
BR9910202A (pt) Sistema de substâncias
MXPA04001916A (es) Etiquetas moleculares para sistemas de solventes organicos.
DE60035490D1 (de) Separin inhibitoren, verfahren zu ihren identifizierung und ihre anwendungen
EA199800867A1 (ru) Соединения тетрагидробетакарболина
DK1506313T3 (da) Fremgangsmåder til screening af modulatorer af den mitokondrielle NAD-afhængige deacetylase SIRT3
ATE478156T1 (de) Verfahren zur identifizierung von modulatoren der eoxin-bildung
ATE420176T1 (de) Der eaat2-promotor und dessen verwendung
NO20033921L (no) Inhibitor av monoaminopptak
DE60320844D1 (de) Kristallstruktur der glutamatracemase (muri)
WO2001012838A3 (en) Compounds which modulate the activity of an lpa receptor
WO2005069859A3 (en) Compositions and methods for modulating dhr96
ATE346915T1 (de) Hybrid topoisomerasen und ihre verwendung